Filing Details

Accession Number:
0000891293-10-000047
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-12-02 19:22:49
Reporting Period:
2010-11-30
Filing Date:
2010-12-02
Accepted Time:
2010-12-02 19:22:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
891293 Cell Therapeutics Inc CTIC Pharmaceutical Preparations (2834) 911533912
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1041084 Phd M Phillip Nudelman 501 Elliott Ave W, #400
Seattle WA 98119
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-11-30 700 $0.35 2,394,165 No 4 S Direct
Common Stock Disposition 2010-11-30 700 $0.35 2,393,465 No 4 S Direct
Common Stock Disposition 2010-11-30 700 $0.35 2,392,765 No 4 S Direct
Common Stock Disposition 2010-11-30 1,900 $0.35 2,390,865 No 4 S Direct
Common Stock Disposition 2010-11-30 5,000 $0.35 2,385,865 No 4 S Direct
Common Stock Disposition 2010-11-30 2,400 $0.35 2,383,465 No 4 S Direct
Common Stock Disposition 2010-11-30 600 $0.35 2,382,865 No 4 S Direct
Common Stock Disposition 2010-11-30 2,700 $0.35 2,380,165 No 4 S Direct
Common Stock Disposition 2010-11-30 9,200 $0.35 2,370,965 No 4 S Direct
Common Stock Disposition 2010-11-30 7,500 $0.36 2,363,465 No 4 S Direct
Common Stock Disposition 2010-11-30 2,300 $0.36 2,361,165 No 4 S Direct
Common Stock Disposition 2010-11-30 1,800 $0.36 2,359,365 No 4 S Direct
Common Stock Disposition 2010-11-30 900 $0.36 2,358,465 No 4 S Direct
Common Stock Disposition 2010-11-30 1,700 $0.36 2,356,765 No 4 S Direct
Common Stock Disposition 2010-11-30 1,900 $0.36 2,354,865 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.